Cure My Disease

Don't miss your cure!

 Log in / Sign up

Exosomes: the decoy receptors that may sabotage lymphoma treatment

NCT ID NCT03985696

Knowledge-focused Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study investigates why some aggressive B-cell lymphomas stop responding to immunotherapy. Researchers are looking at tiny particles called exosomes that are released by tumor cells and may act as decoys, soaking up therapeutic antibodies before they can reach the cancer. By analyzing blood samples from patients and healthy volunteers, the team hopes to understand how exosomes contribute to treatment resistance and whether they could serve as early warning signs of poor outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could reveal why some lymphomas stop responding to immunotherapy and point toward new ways to overcome that resistance.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and findings from lab experiments may not translate to real-world patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Jul 2019

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : * patients over 18 years old with DLBCL at diagnostic or relapsed patients after R-CHOP therapy. * Healthy volunteers over 18 years old Exclusion Criteria: * other B cell diseases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma, B-cell, aggressive non-Hodgkin (B-NHL)

Contacts and locations

Locations

  • University Hospital Limoges

    Limoges, 87042, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.